great work by mgt
obviously the Japanese partner sees value in working together with Pharmaust
Togethor with working with a Top5 major pharma company on R and D for ppl-1 in animals
Many multiples of cuurent shareprice on positive news flow...
also the costs for PAA are reduced by the Japanese partner synthesiseing some 80 analogues of PPL-1
PPL-1 ,Commercial development -that's what we want to see
,for cancer patients,and shareholder value.
If we get news ,,,,,,,,,,,,,,
Sucessful outcome for animal trial,what should the Shareprice be ?
Ann: Research Collaboration & Joint Patent with Japanese Company, page-6
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.020(9.30%) |
Mkt cap ! $86.77M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.5¢ | $562.4K | 2.834M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 64065 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 115000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |